NCT06688240View on ClinicalTrials.gov

A Multi-center, Single-arm, Prospective Non-interventional Study to Investigate the Safety Profiles and Effectiveness of Liposomal Irinotecan (ONIVYDE®) in Combination with 5-fluorouracil (5-FU) and Leucovorin (LV) in Chinese Patients with Metastatic Pancreatic Cancer As Approval Condition (SEOPAC)

Not yet recruitingOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Metastatic Pancreatic Cancer
Sponsors

Collaborators (1)

Les Laboratoires Servier
All Listed Sponsors
collaborator

Les Laboratoires Servier

UNKNOWN

lead

Servier (Tianjin) Pharmaceutical Co. LTD.

INDUSTRY

NCT06688240 - A Multi-center, Single-arm, Prospective Non-interventional Study to Investigate the Safety Profiles and Effectiveness of Liposomal Irinotecan (ONIVYDE®) in Combination with 5-fluorouracil (5-FU) and Leucovorin (LV) in Chinese Patients with Metastatic Pancreatic Cancer As Approval Condition (SEOPAC) | Biotech Hunter | Biotech Hunter